788 related articles for article (PubMed ID: 18302019)
21. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
22. Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain.
Llort G; Muñoz CY; Tuser MP; Guillermo IB; Lluch JR; Bale AE; Franco MA
Hum Mutat; 2002 Mar; 19(3):307. PubMed ID: 11857748
[TBL] [Abstract][Full Text] [Related]
23. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer.
Blanco A; de la Hoya M; Balmaña J; Ramón y Cajal T; Teulé A; Miramar MD; Esteban E; Infante M; Benítez J; Torres A; Tejada MI; Brunet J; Graña B; Balbín M; Pérez-Segura P; Osorio A; Velasco EA; Chirivella I; Calvo MT; Feliubadaló L; Lasa A; Díez O; Carracedo A; Caldés T; Vega A
Breast Cancer Res Treat; 2012 Feb; 132(1):307-15. PubMed ID: 22052327
[TBL] [Abstract][Full Text] [Related]
24. Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes.
Cortesi L; Turchetti D; Bertoni C; Zanocco-Marani T; Vinceti M; Silvestri C; Federico M; Silingardi V; Ferrari S
Eur J Hum Genet; 2003 Mar; 11(3):210-4. PubMed ID: 12673274
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
[TBL] [Abstract][Full Text] [Related]
26. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
27. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P
Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267
[TBL] [Abstract][Full Text] [Related]
28. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J
Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859
[TBL] [Abstract][Full Text] [Related]
29. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
30. Penetrance analysis of the PALB2 c.1592delT founder mutation.
Erkko H; Dowty JG; Nikkilä J; Syrjäkoski K; Mannermaa A; Pylkäs K; Southey MC; Holli K; Kallioniemi A; Jukkola-Vuorinen A; Kataja V; Kosma VM; Xia B; Livingston DM; Winqvist R; Hopper JL
Clin Cancer Res; 2008 Jul; 14(14):4667-71. PubMed ID: 18628482
[TBL] [Abstract][Full Text] [Related]
31. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
32. Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes.
Kaufman DJ; Beaty TH; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):1045-52. PubMed ID: 14578141
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
[TBL] [Abstract][Full Text] [Related]
34. Mutation analysis of PALB2 gene in French breast cancer families.
Damiola F; Schultz I; Barjhoux L; Sornin V; Dondon MG; Eon-Marchais S; Marcou M; ; Caron O; Gauthier-Villars M; de Pauw A; Luporsi E; Berthet P; Delnatte C; Bonadona V; Maugard C; Pujol P; Lasset C; Longy M; Bignon YJ; Fricker JP; Andrieu N; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Muller D
Breast Cancer Res Treat; 2015 Dec; 154(3):463-71. PubMed ID: 26564480
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer.
Fernandes PH; Saam J; Peterson J; Hughes E; Kaldate R; Cummings S; Theisen A; Chen S; Trost J; Roa BB
Cancer; 2014 Apr; 120(7):963-7. PubMed ID: 24415441
[TBL] [Abstract][Full Text] [Related]
36. Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
Hadjisavvas A; Charalambous E; Adamou A; Neuhausen SL; Christodoulou CG; Kyriacou K
Cancer Genet Cytogenet; 2004 Jun; 151(2):152-6. PubMed ID: 15172753
[TBL] [Abstract][Full Text] [Related]
37. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
[TBL] [Abstract][Full Text] [Related]
38. Mutation analysis of the gene encoding the PALB2-binding protein MRG15 in BRCA1/2-negative breast cancer families.
Rio Frio T; Haanpää M; Pouchet C; Pylkäs K; Vuorela M; Tischkowitz M; Winqvist R; Foulkes WD
J Hum Genet; 2010 Dec; 55(12):842-3. PubMed ID: 20844547
[TBL] [Abstract][Full Text] [Related]
39. Screening of male breast cancer and of breast-ovarian cancer families for BRCA2 mutations using large bifluorescent amplicons.
Pages S; Caux V; Stoppa-Lyonnet D; Tosi M
Br J Cancer; 2001 Feb; 84(4):482-8. PubMed ID: 11207042
[TBL] [Abstract][Full Text] [Related]
40. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
